Tech Company Financing Transactions
AcuraStem Funding Round
AcuraStem, based in Pasadena, secured $4 million from California Institute for Regenerative Medicine.
Transaction Overview
Company Name
Announced On
9/3/2024
Transaction Type
Debt
Amount
$4,000,000
Round
Undisclosed
Proceeds Purpose
This latest funding will specifically support AcuraStem's continued efforts to advance its targeted therapeutic program for the UNC13A gene, using its iNeuroRx® technology platform.
Company Information
Company Status
Private & Independent
Industry
Life Sciences
Mailing Address
150 North Orange Grove Blvd. 220
Pasadena, CA 91103
USA
Pasadena, CA 91103
USA
Phone
Website
Email Address
Overview
Collaborators with synergistic skills in disease modeling, AI, bioinformatics, and drug discovery, AcuraStem's co-founders discovered PIKFYVE as a therapeutic target for ALS and FTD in a project led by co-founder Dr. Justin Ichida and published in Nature Medicine in 2018. The company has since established the iNeuroRx® technology platform, built out its team incorporating world-class antisense oligonucleotide (ASO) expertise, and established a growing pipeline of treatments.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Sam Alworth
Vice President
Wen-Hsuan Chang
Browse more venture capital transactions:
Prev: 9/3/2024: Front Row Group venture capital transaction
Next: 9/3/2024: Circle Pharma venture capital transaction
Share this article
Where The Data Comes From
We report on tech company VC transactions. VC investment data records reported here come from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs